{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T14:48:01Z","timestamp":1764859681285,"version":"build-2065373602"},"reference-count":30,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T00:00:00Z","timestamp":1728172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Soonchunhyaung University Research Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Immune checkpoint inhibitors (ICIs), which target immune checkpoints in cancer cells, are increasingly used as a mainstay in anticancer treatment. The combination of atezolizumab and bevacizumab is also a first-line treatment for hepatocellular carcinoma (HCC). However, ICIs can cause immune-related adverse events (IrAEs) which range from mild to severe, potentially leading to the need for discontinuing immunotherapy. We report a case of a pneumothorax, a rare side effect caused by IrAEs. Materials and Methods: This paper reports a case of a 78-year-old male HCC patient who developed a recurrent pneumothorax, suspected to be an adverse effect of ICIs. Results: The patient was a current smoker with a 30 pack-year smoking history. Prior to initiating ICIs, a chest CT scan showed mild emphysema and fibrosis attributable to smoking. Following ICI treatment, the patient developed a recurrent pneumothorax. Further tests revealed no underlying cause for the pneumothorax other than the ICIs and smoking, and there were no signs of intrapulmonary metastasis or pneumonitis. Conclusions: When a pneumothorax occurs in a patient undergoing immunotherapy, it is important to consider it as a potential adverse effect of the treatment. Special attention should be given to the possibility that immunotherapy may exacerbate underlying lung conditions. Patients should be advised on the importance of smoking cessation. As there are currently no guidelines for resuming immunotherapy after a pneumothorax, it is crucial to weigh the risks and benefits and consider dose reduction or discontinuation of the medication.<\/jats:p>","DOI":"10.3390\/medicina60101634","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T06:23:18Z","timestamp":1728282198000},"page":"1634","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Potential Pneumothorax Induced by Immune Checkpoint Inhibitors: A Case Report and Literature Review"],"prefix":"10.3390","volume":"60","author":[{"given":"Yoon-E","family":"Shin","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5214-7430","authenticated-orcid":false,"given":"Hyuk","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7802-0381","authenticated-orcid":false,"given":"Jeong-Ju","family":"Yoo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8694-777X","authenticated-orcid":false,"given":"Sang Gyune","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7113-3623","authenticated-orcid":false,"given":"Young Seok","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"274","DOI":"10.17998\/jlc.2024.08.13","article-title":"Evolving trends in treatment patterns for hepatocellular carcinoma in Korea from 2008 to 2022: A nationwide population-based study","volume":"24","author":"Han","year":"2024","journal-title":"J. Liver Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"622","DOI":"10.17998\/jlc.2024.03.13","article-title":"Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide","volume":"24","author":"Kim","year":"2024","journal-title":"J. Liver Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Korean Liver Cancer Association, and Korean National Cancer Center (2023). 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. J. Liver Cancer, 23, 1\u2013120.","DOI":"10.17998\/jlc.2022.11.07"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.17998\/jlc.2023.11.21","article-title":"Complications of immunotherapy in advanced hepatocellular carcinoma","volume":"24","author":"Song","year":"2024","journal-title":"J. Liver Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune Checkpoint Blockade in Cancer Therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"11057","DOI":"10.1200\/JCO.2024.42.16_suppl.11057","article-title":"Overlapping and non-overlapping indications for checkpoint inhibitors in the US","volume":"42","author":"Paul","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"316","DOI":"10.17998\/jlc.2023.09.04","article-title":"A multidisciplinary approach with immunotherapies for advanced hepatocellular carcinoma","volume":"23","author":"Lee","year":"2023","journal-title":"J. Liver Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Iranzo, P., Callejo, A., Assaf, J.D., Molina, G., Lopez, D.E., Garcia-Illescas, D., Pardo, N., Navarro, A., Martinez-Marti, A., and Cedres, S. (2022). Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer. Front. Med., 9.","DOI":"10.3389\/fmed.2022.875974"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000509081","article-title":"Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors","volume":"106","year":"2021","journal-title":"Pharmacology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"vii59","DOI":"10.1093\/rheumatology\/kez308","article-title":"Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors","volume":"58","author":"Weinmann","year":"2019","journal-title":"Rheumatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2217\/imt-2020-0233","article-title":"Secondary pneumothorax during immunotherapy in two patients with metastatic solid tumors; a new entity","volume":"13","author":"Kucukarda","year":"2021","journal-title":"Immunotherapy"},{"key":"ref_13","first-page":"101258","article-title":"Acute pneumothorax due to immunotherapy administration in non-small cell lung cancer","volume":"31","author":"Sardeli","year":"2020","journal-title":"Respir. Med. Case Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1200\/JCO.2022.40.4_suppl.379","article-title":"Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA","volume":"40","author":"Chan","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.21037\/jtd-23-588","article-title":"Efficacy and safety of durvalumab + chemotherapy vs. atezolizumab + chemotherapy in the treatment of small-cell lung cancer: A retrospective comparative cohort study","volume":"15","author":"Zou","year":"2023","journal-title":"J. Thorac. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jhep.2020.11.026","article-title":"Systemic treatment of HCC in special populations","volume":"74","author":"Rimassa","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"262","DOI":"10.17998\/jlc.2023.07.17","article-title":"The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma","volume":"23","author":"Lee","year":"2023","journal-title":"J. Liver Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Chennamadhavuni, A., Abushahin, L., Jin, N., Presley, C.J., and Manne, A. (2022). Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.779691"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41584-022-00841-0","article-title":"Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases","volume":"18","author":"Tison","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S1470-2045(22)00368-0","article-title":"Immune checkpoint inhibitors in kidney transplant recipients: A multicentre, single-arm, phase 1 study","volume":"23","author":"Carroll","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e000406","DOI":"10.1136\/esmoopen-2018-000406","article-title":"Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): A review of the literature","volume":"3","author":"Norum","year":"2018","journal-title":"ESMO Open"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1093\/jnci\/djab116","article-title":"Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer","volume":"113","author":"Wang","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1002\/cncr.33780","article-title":"Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors","volume":"127","author":"Foster","year":"2021","journal-title":"Cancer"},{"key":"ref_25","first-page":"173","article-title":"Pneumothorax following combination chemotherapy with bevacizumab: A case report and review of the literature","volume":"11","author":"Alrifai","year":"2019","journal-title":"Mol. Clin. Oncol."},{"key":"ref_26","first-page":"e27338","article-title":"Pneumothorax as a Complication of Bevacizumab-Containing Chemotherapy: A Systematic Review of Case Reports","volume":"14","author":"Rehman","year":"2022","journal-title":"Cureus"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.jpedsurg.2015.01.005","article-title":"Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory\/recurrent solid tumors","volume":"50","author":"Interiano","year":"2015","journal-title":"J. Pediatr. Surg."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Nakano, K., Motoi, N., Tomomatsu, J., Gokita, T., Ae, K., Tanizawa, T., Matsumoto, S., and Takahashi, S. (2016). Risk factors for pneumothorax in advanced and\/or metastatic soft tissue sarcoma patients during pazopanib treatment: A single-institute analysis. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2786-z"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1172\/JCI10259","article-title":"Inhibition of VEGF receptors causes lung cell apoptosis and emphysema","volume":"106","author":"Kasahara","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Sabath, B., Muhammad, H.A., Balagani, A., Ost, D.E., Vakil, E., Ahmed, T., Vial, M.R., and Grosu, H.B. (2018). Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4858-8"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/10\/1634\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:11:26Z","timestamp":1760112686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/10\/1634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,6]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["medicina60101634"],"URL":"https:\/\/doi.org\/10.3390\/medicina60101634","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2024,10,6]]}}}